FDA Grants Protalix Orphan Drug Designation For prGCD

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA's Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company's proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.